LAUSR

Barbee, M. S., Ogunniyi, A., Horvat, T., & Dang, T. (2015). Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembroluzimab, and nivolumab in oncology. Annals of Pharmacotherapy, 49(8), 907–937. Bristol-Myers Squibb Company. (2014). Opdivo R © (nivolumab): Highlights of prescribing information. Princeton, NJ: Author. Bristol-Myers Squibb Company. (2015). Yervoy R © (ipilimumab): Highlights of prescribing information. Princeton, NJ: Author. Chae, Y. K., Chiec, L., Mohinra, N., Gentzler, R., Patel, J., & Giles, F. (2017). A case of pembrolizumab-induced Type 1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced Type 1 diabetes. Cancer Immunology, Immunotherapy: CII, 66(1), 25–32. Gaudy, C., Clevy, C., Monestier, S., Dubois, N., Preau, Y., Mallet, S., . . . Beliard, S. (2015). Anti-PD1 pembrolizumab can induce exceptional fulminant Type 1 diabetes. Diabetes Care, 38, e182–e183. Hansen, E., Sahasrabudhe, D., & Sievert, L. (2016). A case report of insulin-dependent diabetes as immunerelated toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunology, Immunotherapy, 65, 765–767. Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., . . . Heinzerling, L. M. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190–209. Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. (2015). Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care, 38, e55–e57. Martin-Liberal, J., Furness, A., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015). Anti-programmed cell death-1 therapy and insulin-dependent diabetes: A case report. Cancer Immunology, Immunotherapy: CII, 64, 765–767. Mellati, M., Eaton, K. D., Brooks-Worrell, B. M., Hagopian, W. A., Martins, R., Palmer, J. P., & Hirsch, I. B. (2015). Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing Type 1 diabetes. Diabetes Care, 38, e137–e138. Merck & Company, Inc. (2014). Kaytruda R © (pembrolizumab): Highlights of prescribing information. Whitehouse Station, NJ: Author. Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016). Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant Type 1 diabetes. Tohoku Journal of Experimental Medicine, 239, 155–158. Munakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2017). Fulminant Type 1 diabetes associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. International Journal of Hematology, 105(3), 383–386. Okamoto, M., Okamoto, M., Gotoh, K., Takayuki, M., Yoshinori, O., Hisae, A., . . . Hirotaka, S. (2016). Fulminant Type 1 diabetes mellitus with antiprogrammed cell death-1 therapy. Journal of Diabetes Investigation, 7, 915–918. Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., . . . Yamamoto, A. (2016). Case of Type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. Journal of Dermatology, 44, 605–606.